Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid plus samarium-153 lexidronam versus zoledronic acid for painful bone metastases from hormone-refractory prostate cancer
2011-005327-41Phase 4Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2012
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in prostate cancer (PCa) and bone metastases comparing Zoledronic acid + samarium-153 lexidronam with Zoledronic acid (2 arms). Started Mar 2012; status: active.
02
Drugs
zoledronic acidsamarium-153 lexidronam
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on 2011-005327-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005327-41.